Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2024; 16(5): 1690-1704
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.1690
Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies
Shu-Chang Nie, Yan-Hua Jing, Lu Lu, Si-Si Ren, Guang Ji, Han-Chen Xu
Shu-Chang Nie, Yan-Hua Jing, Lu Lu, Si-Si Ren, Guang Ji, Han-Chen Xu, Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Lu Lu, Guang Ji, Han-Chen Xu, Shanghai Frontiers Science Center of Disease and Syndrome Biology of Inflammatory Cancer Transformation, Shanghai 200032, China
Guang Ji, Han-Chen Xu, State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine (Shanghai University of Traditional Chinese Medicine), Shanghai 200032, China
Co-first authors: Shu-Chang Nie and Yan-Hua Jing.
Co-corresponding authors: Guang Ji and Han-Chen Xu.
Author contributions: Nie SC and Jing YH contributed to original draft preparation and image drawing; Nie SC was mainly responsible for writing the manuscript on the background knowledge of MDSC and the mechanism involved in immune regulation; Jing YH was mainly responsible for writing the manuscript on the therapeutic strategy of targeting MDSC; Ren SS participated in literature collection; Lu L, Ji G and Xu HC revised the manuscript; all authors wrote, read, and approved the final manuscript. Nie SC and Jing YH contributed equally to this work. The research was performed as a collaborative effort, and the designation of co-first authors authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. The reasons for designating Ji G and Xu HC as co-corresponding authors are twofold. Ji G and Xu HC were the co-corresponding authors of this manuscript because they discussed and selected topics together and developed the framework of the entire manuscript; And after the first draft was completed, they revised and improved the manuscript together, they jointly guided the completion of this manuscript and made the same contribution to this manuscript.
Supported by National Natural Science Foundation of China, No. 82320108022, No. 82322076 and No. 82104466.
Conflict-of-interest statement: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Han-Chen Xu, MD, PhD, Doctor, Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, No. 725 South Wanping Road, Xuhui District, Shanghai 200032, China. hanson0702@126.com
Received: December 27, 2023
Peer-review started: December 27, 2023
First decision: January 16, 2024
Revised: January 30, 2024
Accepted: March 11, 2024
Article in press: March 11, 2024
Published online: May 15, 2024
Processing time: 134 Days and 10.5 Hours
Core Tip

Core Tip: Severe immunosuppression is a hallmark of colorectal cancer (CRC). Myeloid-derived suppressor cells (MDSCs), one of the most abundant components of the tumor stroma, play an important role in the invasion, metastasis, and immune escape of CRC. In this study, we focused on the mechanisms through which MDSCs contribute to the immunosuppressive microenvironment, current therapeutic approaches and technologies targeting MDSCs, and the therapeutic potential of modulating MDSCs in CRC treatment. This study provides ideas and methods to enhance survival rates in patients with CRC.